CMS Proposal To Expand Aprepitant Coverage Could Also Benefit Tesaro’s Rolapitant
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS’ proposed update to its Medicare Part B National Coverage Determination would provide payment for aprepitant when used for patients receiving moderately emetogenic chemotherapy, not just highly emetogenic treatments.